Medicenna TherapeuticsMDNAF +9.49%29 Market Cap is $25.68 Mil as of Jul. 01, 2026. GuruFocus rates MDNAF with a GF Score™ of 29/100. The stock has 1 warning sign investors should review. Among 1,427 Biotechnology companies, Medicenna Therapeutics ranks worse than 73.23% on this metric.
Medicenna Therapeutics's quarterly market cap
declined
from Sep. 2025 ($59.18 Mil) to Dec. 2025 ($56.41 Mil) and
declined
from Dec. 2025 ($56.41 Mil) to Mar. 2026 ($38.37 Mil).
Medicenna Therapeutics's annual market cap
declined
from Mar. 2024 ($95.40 Mil) to Mar. 2025 ($53.19 Mil) and
declined
from Mar. 2025 ($53.19 Mil) to Mar. 2026 ($38.37 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Medicenna Therapeutics's Enterprise Value for Today is $23.80 Mil.
Medicenna Therapeutics (OTCPK:MDNAF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Medicenna Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medicenna Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medicenna Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Medicenna Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Medicenna Therapeutics's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medicenna Therapeutics (MDNAF) has a Market Cap of $25.68 Mil as of Jul. 01, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Medicenna Therapeutics and its competitors. According to the industry distribution chart, Medicenna Therapeutics ranks #1045 out of 1427 companies in the Biotechnology industry, placing it in the top 73.2%.
Is Medicenna Therapeutics' Market Cap too high?
Medicenna Therapeutics' current Market Cap is $25.68 Mil. The Biotechnology industry median Market Cap is 119.57. Medicenna Therapeutics' value of $25.68 Mil is 78.5% below this industry median. Based on the distribution chart, Medicenna Therapeutics ranks #1045 out of 1427 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Medicenna Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Medicenna Therapeutics' Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medicenna Therapeutics ranks #1045 out of 1427 companies for Market Cap. This places Medicenna Therapeutics in the lower half of its industry. The industry median Market Cap is 119.57. Medicenna Therapeutics' value of $25.68 Mil is 78.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.57, based on 1,427 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medicenna Therapeutics's current Market Cap of $25.68 Mil is 78.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Medicenna Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 119.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medicenna Therapeutics's current Market Cap is $25.68 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicenna Therapeutics stock overvalued right now?
Medicenna Therapeutics (MDNAF) has a current Market Cap of $25.68 Mil. The current Market Cap is $25.68 Mil and 78.5% below the Biotechnology industry median of 119.57. Medicenna Therapeutics' overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Medicenna Therapeutics (MDNAF), the current Market Cap is $25.68 Mil as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL-13 Superkines and Empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. Its pipeline candidates include MDNA11 for Cancer immunotherapies, MDNA55 is a Molecular Trojan Horse, and BiSKITs represent a novel platform comprised of Bifunctional SuperKine ImmunoTherapies.
29GF Score
Get the complete analysis for MDNAF
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDNAF has been successfully added to your 
